Rhythm Biosciences Limited (RHY)
Market Open
CXA CXA Primary - Market Cap
- P/E Ratio
- Div Yield
45,729 Volume
- Eps
Want to track RHY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
RHY is not paying dividends to its shareholders.
Rhythm Biosciences Limited has completed 1 stock splits, with the recent split occurring on Aug 05, 2021.
The company's stock is traded on one exchange.
Rhythm Biosciences Limited (RHY) FAQ
On which exchange is it traded?
Rhythm Biosciences Limited is listed on CXA.
What is its stock symbol?
The ticker symbol is RHY.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Rhythm Biosciences Limited ever had a stock split?
Rhythm Biosciences Limited had 1 splits and the recent split was on Aug 05, 2021.
Rhythm Biosciences Limited Profile
| Health Care Technology Industry | Healthcare Sector | - CEO | CXA Exchange | - ISIN |
| Australia Country | - Employees | - Last Dividend | 5 Aug 2021 Last Split | - IPO Date |
Overview
Rhythm Biosciences Limited is a pioneer in the field of medical diagnostics, focusing on the development and commercialization of innovative technologies aimed at improving early disease detection. Incorporated in 2017, the company has rapidly made strides in making advanced diagnostic solutions accessible on a global scale, with its headquarters located in Parkville, Australia. Rhythm Biosciences is dedicated to leveraging cutting-edge research and development to tackle some of the most pressing challenges in healthcare, especially in the realm of cancer detection.
Products and Services
- ColoSTAT® - A revolutionary blood test designed for the early detection of colorectal cancer. This product represents a significant advancement in non-invasive cancer diagnostics, offering a simpler, more accessible alternative to traditional screening methods. ColoSTAT® aims to enhance early detection rates, thereby improving treatment outcomes and survival rates for individuals at risk of colorectal cancer. Rhythm Biosciences' commitment to innovation is embodied in ColoSTAT®, which is at the forefront of their mission to bring life-saving diagnostic tools to the market.
Contact Information
Address: Bio21 Institute
Phone: 61 3 8256 2880
Website: https://www.rhythmbio.com
